{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/measles/background-information/complications/","result":{"pageContext":{"chapter":{"id":"e8947faa-ab89-5369-a4ce-5d229aab4f40","slug":"complications","fullItemName":"Complications","depth":2,"htmlHeader":"<!-- begin field be3a210f-6b54-4f49-8449-860dde4b7947 --><h2>What are the complications?</h2><!-- end field be3a210f-6b54-4f49-8449-860dde4b7947 -->","summary":"","htmlStringContent":"<!-- begin item 09066289-e0eb-413e-b439-d002a59008cc --><!-- begin field 86315ce0-3241-4deb-83d7-5d9e33f31f01 --><ul><li>Complications of measles occur in 10–20% of people in developed countries, but the number may be much higher in developing countries [<a class=\"bibliography-reference internal-reference\" href=\"/topics/measles/references/\">Rota et al, 2016</a>]. </li><li>Susceptibility to opportunistic infection is increased for several weeks after the person has recovered from measles. The reason for this is that the measles virus suppresses the reaction of the immune system to other pathogens [<a class=\"bibliography-reference internal-reference\" href=\"/topics/measles/references/\">Bester, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/measles/references/\">Rota et al, 2016</a>]. Secondary infections of the respiratory tract include [<a class=\"bibliography-reference internal-reference\" href=\"/topics/measles/references/\">PHE, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/measles/references/\">PHE, 2017a</a>]: <ul><li>Otitis media (7–9% of cases).</li><li>Pneumonitis.</li><li>Tracheobronchitis.</li><li>Pneumonia (1–6% of cases).</li></ul></li><li>Central nervous system complications include [<a class=\"bibliography-reference internal-reference\" href=\"/topics/measles/references/\">PHE, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/measles/references/\">Bester, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/measles/references/\">CDC, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/measles/references/\">PHE, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/measles/references/\">WHO, 2018</a>]: <ul><li>Convulsions (about 1 in 200 cases).</li><li>Encephalitis (about 1 in 1000 cases).</li><li>Blindness.</li><li>Subacute sclerosing panencephalitis (SSPE) — a rare but serious degenerative disease of the central nervous system involving seizures and a decline in motor, cognitive, and behavioural function. It affects about 1 in 25,000 people with measles but is up to 16 times more common in children who contract measles at a very young age (less than 1 year). SSPE occurs a median of 7 years after exposure to the virus, although it may occur as late as three decades afterwards, and is invariably fatal.</li></ul></li><li>Diarrhoea affects about 8% of cases and may cause dehydration [<a class=\"bibliography-reference internal-reference\" href=\"/topics/measles/references/\">PHE, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/measles/references/\">WHO, 2018</a>]. </li><li>Complications of measles can be more severe in [<a class=\"bibliography-reference internal-reference\" href=\"/topics/measles/references/\">Ornoy and Tenenbaum, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/measles/references/\">HPA, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/measles/references/\">PHE, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/measles/references/\">Gershon, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/measles/references/\">Carruthers et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/measles/references/\">PHE, 2017a</a>]: <ul><li>Adults, who are more likely to develop complications than children.</li><li>Pregnancy, when it may result in miscarriage, premature birth, and intrauterine death and stillbirth (note: there is no evidence associating measles with congenital defects).</li><li>Immunocompromised people, who are at particular risk of developing severe and prolonged measles and complications such as viral pneumonitis. </li><li>Chronically ill or malnourished children, who can experience more frequent and severe complications. </li><li>Infants, who are more likely to require hospitalisation than older children and are at higher risk of pneumonia, otitis media, SSPE and mortality due to measles. </li></ul></li></ul><!-- end field 86315ce0-3241-4deb-83d7-5d9e33f31f01 --><!-- end item 09066289-e0eb-413e-b439-d002a59008cc -->","topic":{"id":"0ec66249-42a4-5c0d-8a37-f2632ca7acde","topicId":"8b32d801-8035-4957-b21d-fdc0316b697d","topicName":"Measles","slug":"measles","lastRevised":"Last revised in March 2018","chapters":[{"id":"574596e7-391a-5ae2-bf0e-e7a3ac0db310","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"57c95110-4970-53c3-82ca-a0a02f782b1a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"3968756f-72d2-5af8-a135-89adf3df1291","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ef04938f-6cd8-5d2b-8031-e63619ffaae6","slug":"changes","fullItemName":"Changes"},{"id":"109f46c2-752c-5d34-a3a9-70f89ef6e6d8","slug":"update","fullItemName":"Update"}]},{"id":"0ac61cbb-f6a3-5cde-a49e-383cf998866c","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"af44849d-419b-5236-8667-1b06697011e9","slug":"goals","fullItemName":"Goals"},{"id":"8aa254cd-c0c4-5ad2-9778-896548b9ae3d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6e5a7bc2-88e4-5518-9a27-2c4cc8f96d43","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e1e3d298-266c-53ca-a837-a43f7b51f000","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e408b673-3cc9-556a-b3ad-7f2adc0c7e2f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"4bbb33e5-786e-5140-803d-6c7d608ba7fd","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"25608b62-311c-5cfe-bf68-7953a8ee3737","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"da92a2f3-77ca-5048-8cae-2d7f1fbf552e","slug":"definition","fullItemName":"Definition"},{"id":"008ec2dd-b367-561a-8f55-c9d5ced49310","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e8947faa-ab89-5369-a4ce-5d229aab4f40","slug":"complications","fullItemName":"Complications"},{"id":"c8086ee6-6b88-546f-9784-243317583284","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f0a7fac1-bcd1-58ee-bd35-7c7cdd97c2b9","slug":"prevention","fullItemName":"Prevention"}]},{"id":"8a31ee21-9f32-5c22-955c-068539025090","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"258e5d5d-350e-51b5-b153-b71e658fa8b1","slug":"clinical-diagnosis","fullItemName":"Clinical diagnosis"},{"id":"60d5992e-b9ee-5ec0-8c37-2e09959645bf","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"42c95547-93f2-5eb8-a251-1331b9a2fae0","fullItemName":"Management","slug":"management","subChapters":[{"id":"daafe6b6-2230-5141-b9ba-d35b315dae91","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"652a2cc4-a89a-59a8-b1de-8e3927ccc932","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1735c97d-c963-573a-b8b3-b03213e77a02","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"48a021d6-c031-58e0-9b01-8978137c72a8","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c54e239c-eef4-5e71-9082-ef47671dd839","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"aaf0b0cb-35a7-52fb-96f9-e18ff97bd1b0","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6248e49f-183f-5012-b8be-5fecfed55179","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"59da5ba6-9602-5e3c-9fa7-01b556316fbe","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"31dfda31-da84-5592-9695-d7dfc3dbdaee","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"25608b62-311c-5cfe-bf68-7953a8ee3737","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}